By John Q. Hosedrinker 
Moderna Inc. is actively researching potential vaccines to protect against hantaviruses, a deadly pathogen. These early-stage efforts are being conducted in collaboration with the US Army Medical Research Institute of Infectious Diseases and Korea University College of Medicine. This initiative underscores Moderna’s commitment to developing countermeasures for emerging infectious diseases, even as public health experts suggest the current risk from a cruise ship outbreak is minimal.
Read the original article here
The news that Moderna is embarking on early-stage research for a hantavirus vaccine, coinciding with a concerning outbreak on a cruise ship, has certainly set tongues wagging and markets reacting, with Moderna’s shares experiencing a notable jump of 12%. It’s a complex situation, and the immediate reaction seems to be a mix of hope, skepticism, and the ever-present undercurrent of conspiracy.
When thinking about pharmaceutical companies like Moderna, it’s easy to fall into cynical traps. However, there’s a fundamental truth: if everyone dies, there’s no one left to “fleece,” as the saying goes. In their own self-interest, big pharma does indeed benefit from keeping populations alive and, ideally, healthy. We’ve seen this narrative play out before in various public health crises, and this instance feels like another chapter. The prospect of a deadly virus spreading, especially one with a high fatality rate like hantavirus, understandably triggers a sense of urgency and a desire for preventative measures.
The immediate concern, amplified by the cruise ship outbreak, is the potential for rapid spread. Hantavirus is known to be a “lethal motherfucker,” and the thought of it gaining a foothold, especially if it were to become more transmissible, is a sobering one. The comparison to COVID-19 is inevitable, and there’s a clear consensus that this could be far more severe. The unknown factor of transmission – whether it requires close contact with symptomatic individuals or has a longer, less obvious incubation period – adds another layer of anxiety. It’s a stark reminder that while we might feel like we’re living in a “snowglobe” where these events are shaken up for some unknown purpose, the reality of infectious diseases is a persistent threat that requires preparedness.
The mention of Moderna and its mRNA technology is particularly relevant. We recall the scramble for vaccines during the COVID-19 pandemic, and how mRNA platforms offered a significant leap forward in vaccine development speed. This agility is precisely why the announcement of early-stage hantavirus vaccine research is significant. It suggests that the scientific community, and specifically companies like Moderna, are prepared to leverage these advancements to tackle emerging threats. It’s almost as if the market anticipates the development, with stock prices jumping even before the full implications of the research are understood.
However, amidst the pragmatic embrace of scientific progress, there’s also a significant dose of societal commentary. The “MAGA idiots” or those who dismiss vaccines as “fake news” are once again brought into the conversation, highlighting the divisive nature of public health discourse. The sentiment that some will refuse a hantavirus vaccine for “whatever weird reason they choose” is a familiar and frustrating echo of past debates. This highlights a deep chasm in trust and understanding, where scientific advancements are met not just with curiosity but also with outright denial and politicization.
The cruise ship outbreak itself serves as a potent, albeit tragic, catalyst. The idea of a “floating petri dish” and the ensuing panic, coupled with the “vague promise of ‘early-stage research’,” paints a picture of how these events can be perceived. It fuels the narrative that pharmaceutical companies are driven by profit, capitalizing on fear and outbreaks. The question of whether Moderna was already working on a hantavirus vaccine before the cruise ship incident is pertinent, with indications that research was indeed underway due to the general prevalence of hantaviruses, not solely triggered by this specific, albeit deadly, outbreak.
There’s a recognition that hantavirus is not entirely new or unknown. Endemic in many regions, including the US, particularly in rodent populations, the primary mode of transmission involves disturbing infected nests. Simple activities like gathering firewood or cleaning out a shed can expose individuals to the virus. With a significant fatality rate, the development of a vaccine has always been a logical pursuit, independent of any high-profile outbreak. It’s a reminder that the scientific endeavor to combat disease is often a quiet, persistent effort, only amplified when a crisis brings it into sharp public focus.
The discussion also touches upon the broader implications of these outbreaks and the pharmaceutical response. Some express a weariness, feeling as though they are aware of the “snowglobe we’re living in now,” where crises are manufactured or exploited for financial gain. The notion that “they just seem to come along shake it up and see where the money falls” reflects a deep-seated cynicism about the motivations behind such announcements. The idea of repurposing ad campaigns, like a tweaked “Wanta-Fanta?” to market a hantavirus vaccine, adds a darkly humorous touch, underscoring the sometimes jarring commodification of public health.
However, it’s crucial to acknowledge the experiences of individuals who have had adverse reactions to vaccines. Stories of lost sense of smell and breathing difficulties after COVID-19 shots, even when willing participants, contribute to a nuanced and often conflicted public perception. These personal accounts, while not negating the overall benefits of vaccination, highlight legitimate concerns and anxieties that cannot be dismissed. The tension between the individual’s right to choose and the collective need for public health measures is a persistent ethical dilemma.
Furthermore, the conversation delves into the perceived hypocrisy within these debates. The critique that those advocating for bodily autonomy in one context might readily accept government mandates in another underscores a perceived inconsistency. It’s pointed out that the skepticism towards government and big pharma isn’t exclusive to one political faction, suggesting that a deeper societal distrust is at play, manifesting across different groups with varying rationales. The plea for “more understanding and less hateful circle jerks” reflects a desire for a more constructive dialogue.
Ultimately, the announcement of Moderna’s early-stage hantavirus vaccine research, amplified by the tragic cruise ship outbreak, is a multi-faceted event. It showcases scientific innovation and the potential for rapid response to emerging health threats. Simultaneously, it exposes the persistent societal divides, the deep-seated cynicism towards powerful institutions, and the complex interplay between public health, personal autonomy, and economic interests. While the jump in Moderna’s stock price reflects market optimism, the underlying conversation is a rich tapestry of hope, fear, skepticism, and a collective, albeit sometimes fractured, desire to navigate a world where disease remains a constant, evolving challenge.